1. Home
  2. SBFM vs APVO Comparison

SBFM vs APVO Comparison

Compare SBFM & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunshine Biopharma Inc.

SBFM

Sunshine Biopharma Inc.

HOLD

Current Price

$0.17

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFM
APVO
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.3M
IPO Year
2008
2023

Fundamental Metrics

Financial Performance
Metric
SBFM
APVO
Price
$0.17
$1.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 10.1M
33.3K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 0.13
EPS
★ N/A
N/A
Revenue
★ $36,305,891.00
$3,114,000.00
Revenue This Year
$1.23
N/A
Revenue Next Year
$22.44
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 4.11
N/A
52 Week Low
$0.19
$0.53
52 Week High
$21.30
$10.70

Technical Indicators

Market Signals
Indicator
SBFM
APVO
Relative Strength Index (RSI) 25.50 30.88
Support Level N/A $1.37
Resistance Level $1.26 $1.98
Average True Range (ATR) 0.13 0.08
MACD -0.00 0.01
Stochastic Oscillator 0.81 10.40

Price Performance

Historical Comparison
SBFM
APVO

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: